GSK plc (BCBA:GSKD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 151.53T +11.4% |
| Revenue (ttm) | 67.91T +4.3% |
| Net Income | 8.81T -20.8% |
| EPS | 1,169.56 -19.7% |
| Shares Out | n/a |
| PE Ratio | 17.20 |
| Forward PE | 9.75 |
| Dividend | 629.94 (3.13%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | n/a |
| Open | 13.02 |
| Previous Close | 13.17 |
| Day's Range | 13.02 - 13.02 |
| 52-Week Range | 11.00 - 15.96 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK price target lowered to 1,925 GBp from 1,975 GBp at RBC Capital
RBC Capital analyst Trung Huynh lowered the firm’s price target on GSK (GSK) to 1,925 GBp from 1,975 GBp and keeps a Sector Perform rating on the shares. Published first…
Jefferies downgrades GSK on reduced earnings momentum
Jefferies downgraded GSK (GSK) to Hold from Buy with a price target of $55.90, down from $67.40. The stock’s discount to peers has persisted due to perceptions of an earnings…
Glaxo shares slump amid concerns over its vaccine pipeline of new drugs as patent losses loom
The pharmaceutical giant reported beat third-quarter sales and profit expectations, driven by a 15% rise in demand for its specialty HIV and respiratory medicines.
GSK (GSK) Q3 2026 Earnings Call Transcript
Specialty medicines surged 15% as oncology and respiratory treatments drove growth.
What GSK (GSK) Said on Its Q3 Earnings Call
GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit in...
What GSK (GSK) Said on Its Q3 Earnings Call
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and...
GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat
GSK stock toppled early Wednesday after the company's third-quarter vaccine sales fell short, outshining a solid topline.
GSK shares dive as weaker sales and mounting costs unnerve investors
British pharma company reports declining profits amid concerns over looming patent loss of its blockbuster HIV drug Shares in GSK slid on Wednesday despite the UK drugmaker reporting better-than-expec...
GSK plc Earnings Call Transcript: Q3 2026
Q3 sales grew 5% to £8.9bn, led by specialty medicines, and FY2026 guidance was reaffirmed. Strong cash generation supports accelerated R&D, while restructuring costs, pricing pressure and launch execution remain key considerations.
GSK plc Quarterly report: Q3 2026
GSK plc has published its Q3 2026 quarterly earnings report on October 28, 2026.
GSK plc Slides: Q3 2026
GSK plc has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
GSK sees falling vaccine sales take shine off earnings
The drugs giant revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs.
London's FTSE 100 bogged down by GSK, Unilever; budget, Fed in focus
London's FTSE 100 slipped on Wednesday, with Unilever and GSK leading declines after their quarterly results, in a cautious market ahead of finance minister John Healey's first budget and the US Feder...
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Glaxo (GSK) delivered earnings and revenue surprises of +5.00% and +1.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
GSK reports Q3 core EPS 54.6p, up 1% at CER
Reports total Q3 sales GBP 8.9B, +4% AER and +5% CER. “GSK (GSK) has delivered another strong quarter, with our key growth drivers and new launches performing well. We remain…
GSK says ‘on track’ for 2031 sales outlook of over GBP 40B
05:38 EDT GSK (GSK) says ‘on track’ for 2031 sales outlook of over GBP 40B
GSK Sales Get Boost From Specialty Medicines
The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
GSK Q3 Core Operating Profit Rises; Reaffirms 2026 Guidance
(RTTNews) - GSK (GSK, GSK.L, GS71.DE) reported third-quarter profit before tax of 1.935 billion pounds, compared with 2.456 billion pounds in the prior year. Earnings per share declined to 38.5 pence ...
GSK beats third-quarter profit estimates, keeps annual targets
GSK beat third-quarter sales and profit expectations on Wednesday, driven by demand for specialty medicines after the drugmaker began a strategic overhaul under CEO Luke Miels to accelerate growth an...
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update
GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo...
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 ant...
GSK plc Transcript: ESMO 2026 Investor Briefing
ESMO data highlighted ris-rez activity in SCLC and osteosarcoma, mo-rez responses in platinum-resistant ovarian cancer, and high response rates with dostarlimab and zidesamtinib. Five phase III studies are planned for mo-rez across ovarian and endometrial cancers.
GSK plc Slides: FY 2026
GSK plc has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 27, 2026.
GSK’s return to cancer starting to pay off, STAT reports
GSK (GSK) is seeing its return to oncology start to pay off, STAT’s Andrew Joseph reports. In the past week, a cancer drug picked up an approval for another tumor…
GSK to nearly double cancer drugs in trials, WSJ reports
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, the Wall Street Journal reported on Tuesday, citing an interview with a scientist